BIOA.US BioAge Labs, Inc

Healthcare Pharmaceuticals USA Stocks
5.55 USD
Close of Nov 14, 2026
4.81 25.96
Market cap
USD 255M
P/E
-
P/B
0.75x
ROE
-31.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BIOA.US undervalued?

Graham number

The Graham number of BioAge Labs, Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BioAge Labs, Inc fundamental analysis

No fundamental analysis for BioAge Labs, Inc yet.

BioAge Labs, Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BioAge Labs, Inc

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic car…

Full company profile